MeSH D000789 - unstable angina
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Eptifibatide | Eptifibatide |  | 2015-06-12 |  |  |
| Mylan | Bivalirudin | Bivalirudin |  | 2018-06-01 |  |  |
| Eptifibatide | Eptifibatide |  | 2018-07-20 |  |  | |
| Heparin sodium | Heparin |  | 2017-11-30 |  |  | |
| Prasugrel | Prasugrel Mylan |  | 2018-05-15 |  |  | |
| Johnson & Johnson | Abciximab | Reopro |  | 1994-12-22 |  |  |
| GSK | Eptifibatide | Integrilin |  | 1999-07-01 |  |  |
| Sandoz | Bivalirudin | Angiomax | 2028-07-27 | 2000-12-15 |  |  |
| Enoxaparin | Enoxaparin |  | 2010-07-23 |  |  | |
| Heparin sodium | Heparin |  | 2011-06-08 |  |  | |
| Aspen Global | Heparin | Liquaemin |  | 1982-01-01 |  |  |
| Novartis | Heparin, Lidocaine, Dihydroergotamine | Embolex |  | 1984-11-30 |  |  |
| Sanofi | Heparin | Calciparine |  | 1982-01-01 |  |  |
| Enoxaparin | Lovenox |  | 1993-03-29 |  |  | |
| 3M | Heparin | Lipo-hepin |  | 1982-01-01 |  |  |
| Merck & Co | Eptifibatide | Integrilin |  | 1998-05-18 |  |  |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
50%5/10
Phase 3
78%21/27
Approved: 10Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use